Journal article

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Kelly-Anne Phillips, Roger L Milne, Matti A Rookus, Mary B Daly, Antonis C Antoniou, Susan Peock, Debra Frost, Douglas F Easton, Steve Ellis, Michael L Friedlander, Saundra S Buys, Nadine Andrieu, Catherine Nogues, Dominique Stoppa-Lyonnet, Valerie Bonadona, Pascal Pujol, Sue Anne McLachlan, Esther M John, Maartje J Hooning, Caroline Seynaeve Show all

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2013

Grants

Awarded by (Australian) National Breast Cancer Foundation and Cancer Australia


Awarded by Cancer Research UK


Awarded by Dutch Cancer Society


Awarded by Netherlands Organization for Scientific Research


Awarded by Canadian Institutes of Health Research for the INHERIT BRCAs research program


Awarded by Canadian Institute Health Research (CIHR) Team in Familial Risks of Breast Cancer program


Awarded by Canadian Breast Cancer Research Alliance


Awarded by Ministry of Economic Development, Innovation and Export Trade


Awarded by Norwegian European Economic Area (EEA) Financial Mechanism


Awarded by State Budget of the Czech Republic (Regional Center for Applied Molecular Oncology [RECAMO])


Awarded by Red Tematica Investigacion Cooperative en Cancer (RTICC)


Awarded by Red Tematica Investigacion Cooperative en Cancer (ISCIII)


Awarded by National Cancer Institute, National Institutes of Health


Awarded by Cancer Prevention Institute of California


Awarded by Columbia University


Awarded by Fox Chase Cancer Center


Awarded by Huntsman Cancer Institute


Awarded by University of Melbourne


Awarded by Georgetown University Medical Center Informatics Support Center


Awarded by National Breast Cancer Foundation


Awarded by The Francis Crick Institute


Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

Supported by the (Australian) National Breast Cancer Foundation and Cancer Australia Grant No. 628333. International BRCA1 and BRCA2 Carrier Cohort Study (IBCCS) -Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers, UK (EMBRACE) is supported by Cancer Research UK Grants No. C1287/A10118 and C1287/A11990. IBCCS-Gene Etude Prospective Sein Ovaire, France (GENEPSO) is supported by the Fondation de France and the Ligue Nationale Contre le Cancer. IBCCS-Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) is supported by Dutch Cancer Society Grants No. NKI1998 1854, NKI2004-3088, NKI2007-3756 and the Netherlands Organization for Scientific Research Grant No. NWO/91109024. IBCCS-Interdisciplinary Health Research Internal Team Breast Cancer Susceptibility Study (INHERIT) was supported by the Canadian Institutes of Health Research for the INHERIT BRCAs research program (Grant No. CRT43822) and Canadian Institute Health Research (CIHR) Team in Familial Risks of Breast Cancer program (Grant No. CRN87521), the Canadian Breast Cancer Research Alliance (Grant No. 019511), and the Ministry of Economic Development, Innovation and Export Trade (Grant No. PSR-SIIRI 701). IBCCS-National Institute of Oncology (NIO) Hungary was funded by European Against Cancer (subcontract between International Agency for Research on Cancer Lyon and NIO Budapest). This study at NIO, Budapest, Hungary, was supported in part by Norwegian European Economic Area (EEA) Financial Mechanism (Grant No. HU0115/NA/2008-3/OP-9). IBCCS-Brno, Masaryk Memorial Cancer Institute (MMCI), Czech Republic was supported by IBCCS and by the European Regional Development Fund and the State Budget of the Czech Republic (Regional Center for Applied Molecular Oncology [RECAMO], Grant No. CZ.1.05/2.1.00/03.0101). IBCCS-Molecular Oncology Laboratory, Madrid (MOL) was supported by Grant No. RD06/0020/0021 from Red Tematica Investigacion Cooperative en Cancer (RTICC; ISCIII), Spanish Ministry of Economy and Competitivity. The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) and the kConFab Follow-Up Study are supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council, and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. The Breast Cancer Family Registry (BCFR) was supported by the National Cancer Institute, National Institutes of Health under Grant No. UMICA164920 and through cooperative agreements with members of the BCFR and principal investigators, including Cancer Care Ontario (Grant No. U01 CA69467), Cancer Prevention Institute of California (Grant No. U01 CA69417), Columbia University (Grant No. U01 CA69398), Fox Chase Cancer Center (Grant No. U01 CA69631), Huntsman Cancer Institute (Grant No. U01 CA69446), the University of Melbourne (Grant No. U01 CA69638), and Georgetown University Medical Center Informatics Support Center (Grant No. HHSN261200900010C).